On Monday, Aquestive Therapeutics Inc (NASDAQ: AQST) opened higher 5.48% from the last session, before settling in for the closing price of $4.56. Price fluctuations for AQST have ranged from $1.84 to $6.23 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -4.81%. Company’s average yearly earnings per share was noted -234.62% at the time writing. With a float of $77.55 million, this company’s outstanding shares have now reached $91.18 million.
The extent of productivity of a business whose workforce counts for 135 workers is very important to gauge. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Aquestive Therapeutics Inc is 14.94%, while institutional ownership is 45.26%. The most recent insider transaction that took place on Mar 15 ’24, was worth 300,000. In this transaction Chief Innovation/Tech Officer of this company sold 50,000 shares at a rate of $6.00, taking the stock ownership to the 984,476 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Chief Innovation/Tech Officer sold 25,000 for $5.19, making the entire transaction worth $129,685. This insider now owns 1,040,371 shares in total.
Aquestive Therapeutics Inc (AQST) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -234.62% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Check out the current performance indicators for Aquestive Therapeutics Inc (AQST). In the past quarter, the stock posted a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
The latest stats from [Aquestive Therapeutics Inc, AQST] show that its last 5-days average volume of 1.3 million was inferior to 1.74 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 30.79%. Additionally, its Average True Range was 0.33.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 71.14%, which indicates a significant increase from 36.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.32% in the past 14 days, which was lower than the 72.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.98, while its 200-day Moving Average is $3.96. Now, the first resistance to watch is $4.92. This is followed by the second major resistance level at $5.03. The third major resistance level sits at $5.21. If the price goes on to break the first support level at $4.62, it is likely to go to the next support level at $4.44. Assuming the price breaks the second support level, the third support level stands at $4.33.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are currently 91,178K shares outstanding in the company with a market cap of 443.43 million. Presently, the company’s annual sales total 50,580 K according to its annual income of -7,870 K. Last quarter, the company’s sales amounted to 13,540 K and its income totaled -11,510 K.
